OSLO, Norway, February 17, 2026 - Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC).

The article, "Immunobiological mechanisms of action of oncolytic peptides," was created in collaboration with the company's scientific collaborators at the Institut Gustave Roussy (France) and Fox Chase Cancer Center (USA).

Bridging the Gap in Cancer Treatment

While traditional therapies often struggle with "cold" tumors, or cancers that the immune system fails to recognize, oncolytic peptides provide a dual-action solution. The article summarizes how these peptides do more than just destroy cancer cells; they fundamentally reprogram the tumor microenvironment.

Additionally, the publication highlights ruxotemitide (also known as LTX-315/VP-315), Lytix's leading candidate, noting that recent clinical data show that LTX-315 can produce complete and lasting responses in patients with Basal Cell Carcinoma (BCC) and exhibits significant activity in "immunologically cold" tumors that other therapies often overlook.

"This review not only confirms our core scientific approach but also acts as a key resource for the oncology community as we progress toward more oncolytic peptide/molecule-based treatments," said Øystein Rekdal, PhD, Founder and CEO of Lytix Biopharma.

About JITC and SITC

The Journal of ImmunoTherapy of Cancer (JITC) is the official, peer-reviewed journal of the Society for Immunotherapy of Cancer (SITC). As a leading open-access platform for high-impact research, JITC is committed to advancing the science and clinical practice of cancer immunology.

Access the Full Article: https://jitc.bmj.com/content/14/2/e013337

For more information:
Keith Bowermaster, APR, CCMP
Mighty Spark Communications
[email protected]

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit www.lytixbiopharma.com